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IMPORTANCE Generalized anxiety disorder (GAD) is poorly understood compared with other
anxiety disorders, and debates persist about the seriousness of this disorder. Few data exist
on GAD outside a small number of affluent, industrialized nations. No population-based data
exist on GAD as it is currently defined in DSM-5.
OBJECTIVE To provide the first epidemiologic data on DSM-5 GAD and explore cross-national
differences in its prevalence, course, correlates, and impact.
DESIGN, SETTING, AND PARTICIPANTS Data come from theWorld Health OrganizationWorld
Mental Health Survey Initiative. Cross-sectional general population surveys were carried out
in 26 countries using a consistent research protocol and assessment instrument. A total of
147 261 adults from representative household samples were interviewed face-to-face in the
community. The surveys were conducted between 2001 and 2012. Data analysis was
performed from July 22, 2015, to December 12, 2016.
MAIN OUTCOMES ANDMEASURES The Composite International Diagnostic Interviewwas used
to assess GAD along with comorbid disorders, role impairment, and help seeking.
RESULTS Respondents were 147 261 adults aged 18 to 99 years. The surveys had a weighted
mean response rate of 69.5%. Across surveys, DSM-5 GAD had a combined lifetime
prevalence (SE) of 3.7% (0.1%), 12-month prevalence of 1.8% (0.1%), and 30-day prevalence
of 0.8% (0). Prevalence estimates varied widely across countries, with lifetime prevalence
highest in high-income countries (5.0% [0.1%]), lower in middle-income countries (2.8%
[0.1%]), and lowest in low-income countries (1.6% [0.1%]). Generalized anxiety disorder
typically begins in adulthood and persists over time, although onset is later and clinical course
is more persistent in lower-income countries. Lifetime comorbidity is high (81.9% [0.7%]),
particularly with mood (63.0% [0.9%]) and other anxiety (51.7% [0.9%]) disorders. Severe
role impairment is common across life domains (50.6% [1.2%]), particularly in high-income
countries. Treatment is sought by approximately half of affected individuals (49.2% [1.2%]),
especially those with severe role impairment (59.4% [1.8%]) or comorbid disorders (55.8%
[1.4%]) and those living in high-income countries (59.0% [1.3%]).
CONCLUSIONS AND RELEVANCE The findings of this study show thatDSM-5GAD is more
prevalent than DSM-IV GAD and is associated with substantial role impairment. The disorder
is especially common and impairing in high-income countries despite a negative association
between GAD and socioeconomic status within countries. These results underscore the
public health significance of GAD across the globe while uncovering cross-national
differences in prevalence, course, and impairment that require further investigation.
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U nderstanding of generalized anxiety disorder (GAD)has lagged behind understanding of other anxietydisorders.1,2 Since its introduction inDSM-III,3 theGAD
diagnosis has undergone frequent substantial revision, chal-
lenging efforts to accumulate a knowledge base for the disor-
der. Originally, GAD was considered a “wastebasket diagno-
sis”presumedtobeassociatedwithfairlymodest impairment.4,5
AlthoughGADhas evolved into awell-defined condition char-
acterized by excessive, uncontrollable worry, the assumption
thatGAD is associatedwith relativelyminimal impairmenthas
persisted in some circles, with the term “worried well” some-
times used to describe affected individuals.1,6 This assump-
tionmaypartially account for lowerclinical and researchatten-
tion to GAD than to other emotional disorders.7,8
AttentiontoGADhasbeenespecially limitedoutsideasmall
numberof industrialized, affluent countries inwhichnearly all
research on the disorder has been conducted. There is reason
to suspect, however, thatGADmaybe importantnotonly inaf-
fluentcountriesbutalso inotherpartsof theworld. In fact,GAD
might bemore common and impairing in lower-income coun-
tries given the greater economic and political instability, inse-
curity of access to basic necessities, and uncertainty about the
future that tendtocharacterize thosecountries. In linewith this
hypothesis, lower socioeconomic status is associated with
greater mental illness within countries9,10; similar mecha-
nisms could apply across countries as well.
Alternatively, GADmight be less prevalent and impairing
in lower-income countries. A GAD diagnosis requires worries
to be excessive, and this requirement may be met less often
incountrieswhereworrycorresponds torealisticeverydaycon-
cerns. Furthermore, other disorders have been observed to
manifest more frequently through somatic than cognitive
symptoms in non-Western countries,11,12 raising the possibil-
ity that GAD, which is centrally defined by a cognitive symp-
tom (worry), may be less common in developing than devel-
opedcountries.Finally, cross-cultural researchonotherchronic
mental disorders suggests that prevalence is often lower and
outcomes better in less developed countries, perhaps due to
greater provision of support by family and community.13
We explored these competing hypotheses using data from
theWorldMentalHealth(WMH)SurveyInitiative,14acoordinated
series of general population surveys carriedoutunder the aus-
picesof theWorldHealthOrganization (WHO).Two featuresof
thesurveysarenoteworthyforthepresentstudy.First,datawere
collected in26countriesofvarying incomelevels.Thisdiversity
provided an opportunity to isolate universal characteristics of
GAD from characteristics that vary across countries. Second,
by lifting theDSM-IVhierarchyruleprohibiting thediagnosisof
GAD during a mood disorder, the surveys were able to define
GADusingDSM-5 criteria.Toourknowledge, these results rep-
resent the first community epidemiologic data onDSM-5GAD.
Methods
Samples and Procedures
Respondentswere 147 261 adults, ranging in age from18 to99
years,whoparticipated in theWMHsurveys.Data from29sur-
veys in 26 countries are included in this report (Table 1). The
surveys were fielded between 2001 and 2012 and had a
weightedmean response rateof69.5% (eTable 1 in theSupple-
ment). All surveys includednationally or regionally represen-
tative samples of the household population. Sampling and
weightingmethodsaredetailedelsewhere.15Tosummarize re-
sults across surveys,we usedWorld Bank criteria16 to classify
surveys into3country-level incomegroups: (1) low incomeand
lower-middle income, (2) upper-middle income, and (3) high
income.We refer to these groups as low,middle, and high in-
come for ease of presentation.
All surveys used theWHOComposite International Diag-
nostic Interview (CIDI),17 a validated, fully structured, lay-
administered interview. Prior to administration in each coun-
try, theCIDIwas translated, back-translated, andharmonized
using standardizedprocedures.18Consistent trainingand field
quality controlprocedureswereestablishedacross countries.19
Interviews were administered face-to-face in 2 parts. Part 1,
which assessed a core set of mental disorders including GAD,
was administered to all respondents. Part 2, which assessed
additional disorders,was administered to respondentswith a
part 1 disorder plus a probability subsample of other respon-
dents. Comorbidity analyseswere performed using the part 2
sample, which was weighted to adjust for differential prob-
ability of selection into part 2. All other analyses used thepart
1 sample. A human subjects review board or ethics commit-
tee approved the survey protocol in each country (eAppendix
in the Supplement), and all respondents gave informed con-
sent; the mode of consent (written vs oral) varied by survey.
The presence and type of compensation also varied among
surveys.19
Measures
Generalized Anxiety Disorder
The CIDI was used to assess lifetime, 12-month, and 30-day
GAD. In the US survey, lifetime GAD diagnoses based on the
CIDI had good concordance20 with diagnoses based on the
clinician-administered Structured Clinical Interview for
DSM-IV (SCID).21 A clinical reappraisal study including other
WMH surveys did not evaluate GAD in isolation but found
good concordance between CIDI and SCID diagnoses of any
12-month anxiety disorder, including GAD.22 Following the
Key Points
Question What are the patterns and correlates of DSM-5
generalized anxiety disorder throughout the world?
Findings In general population surveys of approximately 150000
adults in 26 countries, DSM-5 generalized anxiety disorder has a
combined lifetime prevalence of 3.7%, 12-month prevalence of
1.8%, and 30-day prevalence of 0.8%. The disorder is significantly
more prevalent and impairing in high-income countries than in
low- or middle-income countries.
Meaning DSM-5 generalized anxiety disorder is more prevalent
than DSM-IV generalized anxiety disorder and is associated with
considerable role impairment, especially in high-income countries,
underscoring its public health significance.
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lead of prior studies that modified the CIDI GAD algorithm to
evaluate specific diagnostic changes,20,23,24 we generated
DSM-5 GAD diagnoses by removing the DSM-IV hierarchical
exclusion of a GAD diagnosis when symptoms occur exclu-
sively during a mood disorder.25 Age of onset (AOO) of GAD
was assessed using probing methods that have been demon-
strated to improve dating accuracy.26 Persistence of GAD
was estimated indirectly by calculating the proportion of
respondents with 12-month GAD among those with the life-
time disorder.
Impairment
Respondents with 12-month GAD were administered an ex-
pandedversionof the SheehanDisability Scale27 to assess role
impairments caused by the disorder during the worst month
in the year before the interview. Respondents rated the ex-
tent of interference with home management, work, close re-
lationships, and social life on separate 0-to-10 scales. We
grouped ratings into categories of absent (0),mild (1-3),mod-
erate (4-6), and severe (7-10) impairment for analysis.Wealso
assessedthenumberofdays in thepast 12monthsduringwhich
respondents reportedbeing totallyunable toworkor carryout
usual activities because of GAD.
Comorbid Disorders
Mentaldisordersother thanGADwerediagnosedusingDSM-IV
criteria. They included other anxiety disorders (ie, panic dis-
order, agoraphobia, social phobia, specific phobia, posttrau-
Table 1. Prevalence ofDSM-5Generalized Anxiety Disorder in theWorldMental Health Surveys
Country
Prevalence, No. (%) [SE]a
Total
Sample,
No.
Lifetime
Prevalence
12-mo
Prevalence
30-d
Prevalence
12-mo Prevalence
Among Lifetime
Cases
Low income 596 (1.6) [0.1] 345 (0.9) [0.1] 186 (0.5) [0.1] 345 (59.5) [2.4] 36 498
Colombia 84 (1.9) [0.3] 39 (1.0) [0.2] 17 (0.4) [0.1] 39 (53.8) [7.7] 4426
Iraq 220 (5.0) [0.6] 131 (3.0) [0.4] 82 (2.0) [0.3] 131 (61.3) [4.4] 4332
Nigeria 8 (0.1) [0] 1 (0.0) [0] 0 1 (32.9) [24.0] 6752
Peru 40 (1.1) [0.1] 17 (0.5) [0.1] 2 (0.1) [0] 17 (44.2) [6.7] 3930
PRC Beijing/Shanghai 60 (1.0) [0.1] 36 (0.6) [0.1] 15 (0.3) [0.1] 36 (61.1) [7.1] 5201
PRC Shenzhen 19 (0.2) [0.1] 14 (0.1) [0.1] 0 14 (76.9) [11.3] 7132
Ukraine 165 (3.3) [0.3] 107 (2.1) [0.2] 70 (1.3) [0.1] 107 (63.1) [3.7] 4725
Middle income 875 (2.8) [0.1] 507 (1.6) [0.1] 231 (0.7) [0.1] 507 (56.1) [2.1] 28 927
Brazil 280 (5.1) [0.4] 187 (3.3) [0.3] 100 (1.8) [0.2] 187 (63.4) [3.8] 5037
Bulgaria 125 (2.3) [0.2] 57 (1.2) [0.1] 23 (0.5) [0.1] 57 (49.5) [4.8] 5318
Colombia (Medellín) 127 (3.8) [0.5] 73 (2.1) [0.3] 31 (0.9) [0.2] 73 (56.2) [5.6] 3261
Lebanon 71 (2.3) [0.3] 47 (1.5) [0.3] 22 (0.6) [0.2] 47 (64.5) [7.5] 2857
Mexico 78 (1.1) [0.2] 44 (0.6) [0.1] 19 (0.3) [0.1] 44 (48.8) [7.7] 5782
Romania 27 (1.0) [0.3] 9 (0.2) [0.1] 8 (0.2) [0.1] 9 (24.5) [8.9] 2357
South Africa 167 (3.6) [0.4] 90 (1.9) [0.3] 28 (0.6) [0.1] 90 (53.5) [4.8] 4315
High income 4417 (5.0) [0.1] 2031 (2.3) [0.1] 850 (0.9) [0] 2031 (45.9) [0.9] 81 836
Australia 710 (8.0) [0.5] 312 (3.6) [0.3] 128 (1.5) [0.2] 312 (45.4) [2.7] 8460
Belgium 75 (2.8) [0.5] 27 (0.9) [0.3] 10 (0.3) [0.1] 27 (31.2) [7.1] 2419
France 190 (6.2) [0.5] 61 (2.1) [0.3] 20 (0.6) [0.2] 61 (33.7) [3.7] 2894
Germany 58 (1.5) [0.2] 22 (0.5) [0.1] 6 (0.2) [0.1] 22 (34.8) [7.5] 3555
Israel 216 (4.4) [0.3] 148 (3.1) [0.3] 50 (1.1) [0.2] 148 (70.7) [3.1] 4859
Italy 100 (2.1) [0.3] 28 (0.6) [0.1] 9 (0.2) [0.1] 28 (28.4) [5.2] 4712
Japan 105 (2.6) [0.3] 53 (1.2) [0.2] 8 (0.2) [0.1] 53 (47.6) [5.0] 4129
New Zealand 1084 (7.9) [0.3] 441 (3.1) [0.2] 187 (1.2) [0.1] 441 (38.5) [2.0] 12 790
Northern Ireland 334 (6.4) [0.4] 150 (2.8) [0.3] 82 (1.5) [0.2] 150 (44.2) [3.2] 4340
Poland 90 (0.9) [0.1] 52 (0.5) [0.1] 25 (0.3) [0.1] 52 (58.4) [5.1] 10 081
Portugal 269 (6.1) [0.5] 145 (3.3) [0.3] 45 (1.1) [0.2] 145 (53.0) [3.2] 3849
Spain 131 (1.9) [0.2] 59 (0.8) [0.2] 33 (0.4) [0.1] 59 (43.8) [6.3] 5473
Spain (Murcia) 193 (7.0) [0.9] 111 (4.3) [0.7] 77 (3.0) [0.6] 111 (61.3) [3.3] 2621
The Netherlands 110 (3.6) [0.4] 28 (1.0) [0.2] 13 (0.4) [0.1] 28 (28.2) [5.8] 2372
United States 752 (7.8) [0.3] 394 (4.0) [0.2] 157 (1.6) [0.2] 394 (52.1) [1.8] 9282
All countries 5888 (3.7) [0.1] 2883 (1.8) [0.1] 1267 (0.8) [0] 2883 (48.8) [0.8] 147 261
Comparison between
individual countriesb
85.8 42.7 29.0 6.7
Comparison between
country income groupsc
311.3 106.5 21.7 20.4
Abbreviation: PRC, People’s Republic
of China.
a The ratio of numerator to
denominator numbers does not
equal the reported percentages
because the percentages are
weighted.
b χ228 Test of homogeneity for
variation in prevalence estimates
across countries; all P < .001.
c χ22 Test of homogeneity for variation
in prevalence estimates across low-,
middle-, and high-income countries;
all P < .001.
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matic stressdisorder, andseparationanxietydisorderwithon-
seteither inchildhoodoradulthood),mooddisorders (ie,major
depression and bipolar spectrum disorder28), disruptive be-
haviordisorders (ie,oppositionaldefiantdisorder, conductdis-
order, intermittent explosive disorder, attention-deficit/
hyperactivity disorder, bulimia nervosa, and binge eating
disorder), andsubstance-relateddisorders (ie, alcoholanddrug
abuse and dependence).
OtherMeasures
Sociodemographic variables included respondent age, sex,
marital status, educational level, household income (strati-
fied into quartileswithin country), and employment status at
the time of the interview. Treatment seekingwas assessed by
askingwhether respondents received treatment for anymen-
tal health or substance-related problem during the past 12
months. Treatment in 4 sectorswas probed: specialtymental
health, generalmedical health, human services, and comple-
mentary-alternative medicine.
Statistical Analysis
Cross-tabulations were used to estimate prevalence, comor-
bidity, impairment, and treatment.Logistic regressionandsur-
vival analysiswereused to examine sociodemographic corre-
lates. The actuarial method29 was used to generate AOO
survival curves. Design-based SEs were estimated using the
Taylor series linearizationmethod30 implemented inSUDAAN
version 11.031 to adjust for dataweighting and clustering. Sta-
tistical significance was evaluated using Wald and McNemar
χ2 tests. All testswere 2-sided and used a significance thresh-
oldofP < .05.Data analysiswasperformed fromJuly22, 2015,
to December 12, 2016.
Results
Prevalence
Across all surveys, the combined lifetime prevalence of GAD
was 3.7%, 12-month prevalence was 1.8%, and 30-day
prevalence was 0.8% (Table 1). Lifetime prevalence esti-
mates varied widely across countries, ranging from less
than 1% of the populations of Nigeria and Shenzhen, China,
to approximately 8% of the populations of Australia, New
Zealand, and the United States. Prevalence increased with
economic development: lifetime estimates (SE) were lowest
in low-income (1.6% [0.1%]), moderate in middle-income
(2.8% [0.1%]), and highest in high-income (5.0% [0.1%])
countries.
Sociodemographic Correlates
Around the world, being female, younger than 60 years, and
unmarried (previously married or never married) were asso-
ciatedwithGAD(eTable2 in theSupplement). Inaddition,GAD
was founddisproportionately in respondentswith lower edu-
cational levels, lower household income, and Other employ-
ment status (mostly unemployed or disabled). These corre-
lateswere relativelymodest inmagnitude (odds ratio [OR], 1.1;
95%CI, 1.0-1.3 toOR, 1.8; 95%CI, 1.7-2.0) except for themark-
edly increased odds of GAD among younger cohorts (OR, 3.0;
95%CI, 2.7-3.3 toOR, 6.0; 95%CI, 5.1-7.0). The pattern of cor-
relates was similar across country groups, although GADwas
associated less consistently with educational level, house-
hold income, and employment status in middle- and low-
income countries.
Onset and Course
Generalized anxiety disorder typically begins in adulthood
(eFigure in the Supplement). Onset before puberty was rare
in these surveys, with only 5% of cases developing by age
13 years. There was a gradual, steady accumulation of new
cases over the lifespan, with 25% of all cases emerging by
25 years, 50% of the cases emerging by 39 years, and 75%
of the cases emerging by 53 years. Although the AOO distri-
bution was shifted earlier for high-income countries (me-
dian AOO, 36 years) relative to middle- and low-income
countries (median AOO, 43 years for both), the distributions
were substantively similar across country groups (χ22 = 1.9,
P = .38).
ConsistentwithconceptualizationsofGADasachronicdis-
order, nearly half of all lifetime cases still had the disorder in
the 12monthsbefore the interview (Table 1).Generalizedanxi-
ety disorder was more persistent in low-income (59.5%) and
middle-income (56.1%) countries than in high-income coun-
tries (45.9%).Aroundtheworld,persistencewashigher forear-
lier-onset GAD cases, for individuals with lower educational
levels and family income, and for those not employed out-
side the home (ie, Other status, homemaker) (eTable 2 in the
Supplement).
Comorbidity
Most individuals with lifetime (81.9% [0.7%]) and 12-month
(70.8% [1.2%])GADhad 1 ormore comorbidDSM-IV/CIDI dis-
orders (Table 2). The oddswerehighest for lifetimemoodand
anxietydisorders, lower fordisruptivebehaviordisorders, and
lowest for substance-related disorders. The singlemost com-
moncomorbidconditionwasmajordepressivedisorder,which
was found in 52.6% (0.9%) of lifetime cases and 40.9% (1.3%)
of 12-month cases of GAD worldwide.
Role Impairment
Respondents with 12-month GAD reported a mean (SE) of
41.2 days (2.4) out of role due to GAD in the past year. Half
(50.6%) of the 12-month cases reported severe functional
impairment resulting from GAD (Table 3). The rate of severe
impairment was lower yet still substantial (35.3%) among
individuals with GAD who had no comorbid disorders
(eTable 3 in the Supplement).
The proportion of participants with severe GAD-related
impairment was highest in high-income (54.5%), lower in
middle-income (42.6%), and lowest in low-income (39.0%)
countries. Generalized anxiety disorder was a more disabling
disorder in some countries than others, with severe impair-
ment reported by a small minority of persons with GAD in
China (17.3% in Shenzhen, 21.8% in Beijing/Shanghai) and
Mexico (28.7%) but by a large majority of those with GAD in
the Netherlands (80.3%) and Romania (82.3%). Neverthe-
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less, the proportion of severely impaired persons was sizable
in most countries (median, 48.6%; interquartile range,
39.4%-56.2%).
Treatment
Approximatelyhalf (49.2%)of respondentswith12-monthGAD
reported receiving some formofmental health treatmentdur-
ing theprevious year (Table 4). Treatmentwas sought dispro-
portionatelyby thosewithcomorbiddisorders (55.8%)butwas
also sought by approximately one-third (32.4%) of respon-
dentswithGADalone (eTable4 in the Supplement). The treat-
ment ratewas higher in high-income (59.0%) than inmiddle-
income (29.1%) or low-income (21.7%) countries. However,
across countries, the overall pattern was of increasing use of
services, particularly specialtymentalhealth services,with in-
creasing impairment due to GAD.
Discussion
Thepresent findings shednewlightonpatternsofGADaround
the globe. First, we showed that diagnostic changes from
DSM-IV toDSM-5 yielded an influx of new GAD cases, as life-
time prevalence estimates reported herein are 37% to 90%
higher thanpublishedestimates forDSM-IVGAD in theUnited
States.32,33 In the current WMH surveys, lifetime prevalence
is37%higherand12-monthprevalence is50%higher forDSM-5
than DSM-IV GAD (Ruscio AM, Hallion LS, Demyttenaere K,
Lee S, Lim CCW. Generalized anxiety disorder. In: Scott KM,
de Jonge P, Stein DJ, Kessler RC, eds. The Cross-National Epi-
demiologyofMentalDisorders:FactsandFiguresFromtheWorld
Mental Health Surveys. Cambridge, England: Cambridge Uni-
versityPress; inpress).Althoughan increase inprevalencewas
Table 2. Comorbidity ofDSM-5Generalized Anxiety DisorderWithDSM-IVMental Disorders Across Countriesa
DSM-IV Disorder
Lifetime GAD 12-mo GAD
No. (%) [SE]b OR (95% CI)c No. (%) [SE]d OR (95% CI)e
Anxiety disorder
Panic disorder 699 (12.3) [0.7] 9.8 (8.6-11.2) 328 (11.8) [0.9] 15.8 (13.3-18.8)
Agoraphobia 506 (9.4) [0.5] 7.0 (6.1-8.0) 246 (9.0) [0.7] 11.3 (9.3-13.7)
Social phobia 1303 (26.1) [0.9] 9.2 (8.4-10.2) 561 (22.6) [1.2] 12.3 (10.7-14.0)
Specific phobia 1171 (25.6) [0.8] 4.4 (4.0-4.8) 546 (25.2) [1.2] 5.6 (4.9-6.4)
Posttraumatic stress disorder 1208 (21.0) [0.7] 9.2 (8.4-10.2) 415 (14.4) [0.8] 10.8 (9.4-12.4)
Childhood-onset separation anxiety disorderf 201 (8.6) [0.7] 4.9 (4.0-6.0)
Adult-onset separation anxiety disorder 390 (15.5) [0.8] 6.1 (5.3-7.1) 94 (6.9) [0.8] 8.2 (6.2-10.7)
Any anxiety disorder 2929 (51.7) [0.9] 8.0 (7.4-8.7) 1257 (44.0) [1.2] 9.3 (8.5-10.3)
Mood disorder
Major depressive disorder 3055 (52.6) [0.9] 10.6 (9.7-11.4) 1173 (40.9) [1.3] 16.3 (14.6-18.2)
Bipolar spectrum disorderg 544 (11.4) [0.6] 7.6 (6.7-8.7) 267 (10.8) [0.8] 11.5 (9.6-13.8)
Any mood disorderh 3657 (63.0) [0.9] 13.4 (12.3-14.4) 1467 (51.1) [1.3] 19.6 (17.6-21.8)
Disruptive behavior disorder
Oppositional defiant disorder 190 (10.7) [0.9] 4.4 (3.5-5.4) 34 (3.5) [0.7] 8.9 (5.5-14.2)
Conduct disorder 142 (7.8) [0.8] 4.3 (3.4-5.4) 11 (1.0) [0.3] 3.6 (1.8-7.2)
Intermittent explosive disorder 342 (15.0) [1.1] 5.7 (4.7-6.8) 149 (12.1) [1.4] 7.1 (5.5-9.3)
Attention-deficit/hyperactivity disorder 158 (7.5) [0.8] 4.6 (3.7-5.8) 68 (5.8) [0.9] 8.3 (6.0-11.5)
Bulimia nervosa 115 (3.8) [0.4] 5.8 (4.5-7.5) 33 (2.4) [0.5] 9.5 (6.0-15.1)
Binge eating disorder 150 (6.1) [0.6] 4.4 (3.5-5.5) 53 (4.3) [0.8] 6.8 (4.6-10.1)
Any disruptive behavior disorder 566 (10.1) [0.6] 4.0 (3.5-4.4) 122 (8.1) [0.8] 6.2 (5.2-7.4)
Substance-related disorder
Alcohol abuse 1004 (19.6) [0.8] 2.5 (2.2-2.7) 149 (5.8) [0.6] 2.9 (2.3-2.6)
Alcohol dependence 490 (8.9) [0.5] 4.6 (3.9-5.3) 106 (4.4) [0.6] 6.0 (4.5-8.1)
Drug abuse 459 (10.5) [0.6] 3.9 (3.4-4.5) 71 (3.6) [0.6] 6.9 (4.8-9.8)
Drug dependence 245 (5.3) [0.4] 5.9 (4.8-7.2) 52 (2.5) [0.5] 10.5 (6.8-16.2)
Any substance-related disorder 1141 (22.5) [0.8] 2.7 (2.5-3.0) 221 (9.1) [0.8] 3.9 (3.2-4.7)
Any mental disorder 4627 (81.9) [0.7] 12.3 (11.2-13.6) 1998 (70.8) [1.2] 14.9 (13.2-16.7)
Abbreviations: GAD, generalized anxiety disorder; OR, odds ratio.
a The ratio of numerator to denominator numbers does not equal the reported
percentages because the percentages are weighted.
b Proportion of respondents with lifetime DSM-5 GADwho also qualified for the
lifetime DSM-IV disorder in each row.
c Based on separate logistic regressionmodels using lifetime GAD to predict
each lifetime comorbid disorder; all significant at P < .001.
d Proportion of respondents with 12-month DSM-5 GADwho also qualified for
the 12-month DSM-IV disorder in each row.
e Based on separate logistic regressionmodels using 12-month GAD to predict
each 12-month comorbid disorder; all significant at P < .001.
f The surveys did not include a 12-month assessment of childhood-onset
separation anxiety disorder.
g Includes bipolar I disorder, bipolar II disorder, or subthreshold bipolar disorder
as defined byMerikangas et al.28
h Includes major depressive episode and bipolar spectrum disorder.
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expected, these estimates reveal that the increase was sub-
stantial.Thenewly identified individuals,whopreviouslywere
barred from a GAD diagnosis by a concomitant mood disor-
der, have been shown in outpatient samples to experience a
particularly severe form of GAD with a high burden of
comorbidity.34,35 Consistentwith this account,we found that
more than 80% of people with lifetime GAD experienced an-
other lifetime disorder, most often major depressive disor-
der. Given the frequent occurrence of GAD during mood epi-
sodes and the implications of comorbidity for treatment,36
these findings underscore the importance of systematic as-
sessmentandappropriatemanagementofGADinpatientswith
mood disorders.
Second, theprevalenceofGADvariedwidely across coun-
tries, with rates generally higher in higher-income countries.
Thismeans that the global prevalence of GADmay be consid-
erably lower thanthepreviousbest-estimate ratesof6.2%(life-
time) and 2.6% (12-month), which were based exclusively on
high-income countries.37 This finding alignswith the broader
pattern of higher rates of psychopathology in wealthier
countries38 that has variously been attributed to methodo-
logic artifacts, differential reporting of mental illness, or dif-
ferences in risk and protective factors across countries.39-41 A
further possibility specific toGAD is that cognitive symptoms
of the disorder may be reported less frequently than somatic
symptoms in developing countries,42,43 implying that clini-
cally significant anxiety in those countries may bemissed by
theDSM-5emphasisonworry.Anotherpossibility is that,when
worry is reported, it may focus on a single dominant concern
(eg, financial worry)44 or fail to be judged as excessive owing
to genuinely difficult life circumstances.45 A simple form of
this explanation is contradicted byhigher rates ofGAD inper-
sons of lower socioeconomic statuswhopresumablyhave the
most stress and fewest resources.Amorenuanced form is that
individual differences in thepropensity toworrymaybemore
evidentunder conditions of relativewealth and stability, such
as those found in high-income countries, than under condi-
tions of relative scarcity and instability, where worry may be
expected and widespread.
The prevalence of DSM-5 GAD was concentrated among
individualswhowere female, younger than 60 years, unmar-
ried, not employed, less educated, and less affluent relative
tonational standards.Contrary tomostmentaldisorders,46on-
set of GAD before adulthood was uncommon, occurring in
fewer than25%of thecases. Instead,newcasesaccruedgradu-
ally from puberty through 65 years. These findings are con-
sistent with previous epidemiologic studies in high-income
countries32,47 and suggest that onset or recognitionof thedis-
order is even later in lower-income countries. The relatively
shallowAOOdistribution seemsunlikely to result from retro-
spective recall biases, as surveys of adolescents have yielded
similar findings.48,49Amoreplausible explanation is thatGAD
may be triggered by stressful life events at any time in the
lifespan,50,51 accounting for thegradual accumulationof cases.
Another possibility is that a temperamental predisposition to
worry, emerging early in life, does not cause marked distress
or impairment until a significant stressor—or chronic stress of
the sort associatedwith the socioeconomic profile character-
istic of GAD—overwhelms the individual’s capacity to keep
worry in check.52,53 OnceGADbegins, it often persists: nearly
half of the individuals with lifetime GADmet 12-month crite-
ria for the disorder. However, persistence variedwidely, with
higherpersistence reported in lower-incomecountries. Taken
together, these findings provide mixed support for conven-
tional views of GADas a chronic condition present since early
life.54-57 Instead,we foundthat theGADsyndromeusually first
emerges in adulthood and that its course, although often un-
remitting, differs substantially by country.
Contrary to some characterizations of GAD as a disease of
the “worried well,”1,6 GAD was associated with marked dis-
ability.Half of the individualswith 12-monthGADreported se-
veredisability in 1 ormore life domains resulting from thedis-
order.Moreover, individuals reported ameanofmore than40
days inthepastyearwhentheywerecompletelyunable towork
or carry out daily activities because of GAD. Finally, GADwas
associated with significant help seeking, with approximately
half of the individuals with 12-month GAD receiving treat-
ment during the past year. Consistentwith conceptions of co-
morbidity as a severity marker,58 individuals whose GAD oc-
curredwith other disorders reported greater disability due to
GADandgreater useofmental health services.However, even
in theabsenceofotherdisorders, one-thirdof individualswith
GAD reported severe impairment and treatment. These re-
sults extend prior findings of general health-related disabil-
Table 3. Severity of Role Impairment AssociatedWith 12-Month Generalized Anxiety Disorder by Country Income Level
Country Income
Proportion With Severe Role Impairment, No. (%) [SE]a,b
Sample
Size, No.Home Work Relationship Social Anyc
Low income 79 (23.2) [2.8] 74 (23.7) [3.3] 79 (26.1) [3.4] 67 (24.6) [3.7] 126 (39.0) [3.6] 345
Middle income 120 (25.8) [2.2] 24 (28.7) [3.0] 123 (26.8) [2.2] 128 (28.4) [2.8] 192 (42.6) [3.0] 507
High income 565 (29.4) [1.3] 625 (34.4) [1.4] 628 (33.0) [1.3] 712 (38.1) [1.4] 1049 (54.5) [1.4] 2031
All countries 764 (28.0) [1.1] 816 (32.1) [1.2] 830 (31.1) [1.1] 907 (34.9) [1.2] 1367 (50.6) [1.2] 2883
Comparison between
countriesd
2.5
(P = .08)
5.4
(P = .004)
4.1
(P = .02)
9.6
(P < .001)
13.0
(P < .001)
a The ratio of numerator to denominator numbers does not equal the reported
percentages because the percentages are weighted.
b Sheehan Disability Scale scores for severe impairment range from 7 to 10.
Respondents rated the extent of interference with homemanagement, work,
close relationships, and social life on separate 0-to-10 scales and were
assigned to a severity category based on their highest impairment rating
across the 4 role domains.
c Proportion with severe role impairment in at least 1 of the 4 Sheehan Disability
Scale role domains.
d χ22 Test of homogeneity for variation in impairment severity across low-,
middle-, and high-income countries.
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ity and diminished quality of life in GAD59-61 by quantifying
the impairment resulting fromGAD ineach lifedomain, show-
ing that impairment is substantial in developing aswell as de-
velopedcountries, anddescribing theassociationbetween im-
pairment and treatment seeking across countries.
Although GAD was impairing in all of the countries in-
cluded in the present study, it was most impairing in high-
income countries. This finding is particularly striking when
contrasted against the greater frequency and persistence of
GAD in individuals with lower socioeconomic status relative
to national standards. The inverse associations with income
at the individual vs national levels have beendocumented for
manymental disorders and could reflect the influence of risk
factors that vary with economic development.62 For ex-
Table 4. Treatment Seeking AssociatedWith 12-Month Generalized Anxiety Disorder as a Function of Impairment Severity and Country Income Level
Treatment Sector
Proportion Who Received Mental Health Treatment in the Past 12 mo, No. (%) [SE]a
All 12-mo GAD Cases
Severity of Role Impairmentb
Mild Moderate Severe
Specialty mental healthc
Low income 14 (3.7) [1.4] 9 (8.4) [3.8]
Middle income 80 (16.5) [2.3] 17 (13.2) [3.9] 40 (22.8) [4.2]
High income 632 (32.3) [1.3] 38 (22.8) [4.7] 128 (23.0) [2.1] 410 (41.8) [2.0]
All countries 726 (26.0) [1.1] 42 (18.1) [3.6] 148 (18.1) [1.6] 459 (35.9) [1.7]
Comparison between countriesd 72.1
(P < .001)
30.5
(P < .001)
23.4
(P < .001)
General medicale
Low income 40 (11.4) [2.2] 13 (11.5) [3.3] 20 (16.0) [4.4]
Middle income 79 (14.7) [2.0] 11 (21.2) [7.0] 17 (10.5) [2.7] 30 (15.9) [3.6]
High income 847 (41.0) [1.4] 64 (36.7) [5.0] 189 (33.4) [2.4] 496 (46.7) [1.9]
All countries 966 (32.8) [1.1] 79 (30.3) [3.9] 219 (26.2) [1.8] 546 (39.4) [1.7]
Comparison between countriesd 76.8
(P < .001)
6.4
(P < .001)
21.9
(P < .001)
35.2
(P < .001)
Human servicesf
Low income 17 (6.4) [2.2] 6 (10.1) [5.6] 8 (4.2) [1.2]
Middle income 19 (3.8) [1.0] 13 (6.9) [2.4]
High income 152 (7.6) [0.8] 8 (4.4) [1.6] 30 (4.9) [1.1] 100 (9.8) [1.2]
All countries 188 (6.8) [0.6] 12 (4.7) [1.5] 37 (4.9) [1.1] 121 (8.9) [1.0]
Comparison between countriesd 4.7
(P = .01)
8.8
(P < .001)
4.3
(P = .01)
Complementary-alternative medicineg
Low income 8 (2.4) [0.9]
Middle income 21 (4.0) [1.5] 12 (7.3) [3.5]
High income 164 (8.2) [0.8] 7 (3.4) [1.4] 37 (6.7) [1.3] 111 (11.6) [1.3]
All countries 193 (6.8) [0.6] 11 (3.6) [1.2] 43 (5.1) [0.9] 126 (10.0) [1.1]
Comparison between countriesd 12.0
(P < .001)
9.9
(P < .001)
Any treatmenth
Low income 71 (21.7) [3.3] 7 (15.9) [5.6] 23 (23.4) [6.4] 35 (27.4) [5.7]
Middle income 156 (29.1) [2.8] 15 (30.0) [7.6] 35 (24.5) [4.8] 70 (35.9) [4.9]
High income 1205 (59.0) [1.3] 91 (51.8) [4.9] 275 (48.7) [2.5] 705 (67.8) [1.9]
All countries 1432 (49.2) [1.2] 113 (43.3) [4.0] 333 (40.7) [2.2] 810 (59.4) [1.8]
Comparison between countriesd 73.6
(P < .001)
7.2
(P < .001)
12.6
(P < .001)
28.7
(P < .001)
Abbreviation: GAD, generalized anxiety disorder.
a Empty cells indicate fewer than 5 cases. The ratio of numerator to
denominator numbers does not equal the reported percentages because the
percentages are weighted.
bBased on GAD-related impairment rated on the Sheehan Disability Scale.
Sheehan Disability Scale scores were categorized as 1 to 3 (mild), 4 to 6
(moderate), and 7 to 10 (severe). Respondents rated the extent of
interference with homemanagement, work, close relationships, and social life
on separate 0-to-10 scales and were assigned to a severity category based on
their highest impairment rating across the 4 role domains.
c Includes psychiatrist, psychologist, or other mental health professional; social
worker or counselor in a mental health specialty setting; use of a mental health
helpline; or overnight admission for a mental health, drug, or alcohol problem,
with a presumption of daily contact with a psychiatrist.
d χ22 Test of homogeneity for variation in treatment estimates across low-,
middle-, and high-income countries. The test was performedwhenmore than
1 stable cell (5 cases) was available for comparison.
e Includes general practitioner, other medical physician, nurse, occupational
therapist, or other health care professional not previously mentioned.
f Includes religious or spiritual advisor, or social worker or counselor in any
setting other than a specialty mental health setting.
g Includes any other type of healer, such as herbalist or homeopath;
participation in an internet support group; or participation in a self-help group.
h Respondents who sought any form of treatment listed above.
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ample, greater industrialization and urbanization in higher-
incomecountriesmay result in fewer community supports (eg,
extended family and religious community) to buffer the im-
pact of stressful events or assist with role functioning. In ad-
dition, theremaybegreaterdemandson individuals inhigher-
income countries to achieve independence, occupational
success, and social status in a competitive environment, in-
creasing uncertainty and perceived pressure to meet high
expectations.63
Limitations
Our large general population sample offered unprecedented
statistical power and the opportunity to study GAD in parts
of the world in which, to our knowledge, no previous data
were available. Nevertheless, the study was limited in sev-
eral respects. Assessment was performed with fully struc-
tured interviews administered by lay interviewers. Clinical
reappraisal studies have shown good concordance with the
SCID but indicate that CIDI-based prevalence estimates tend
to be conservative.22 Lifetime symptoms and disorder onset
were reported retrospectively. Our measure of persistence
could not distinguish chronic from recurrent cases and
missed cases that resolved before the preceding 12 months.
Finally, although the results varied systematically by coun-
try income strata, large differences in prevalence within
strata suggest an influence of methodologic variation
(eg, sample frames and/or response rates) or substantive
factors (eg, sociocultural variables) not accounted for in our
analyses.
Conclusions
Using data from 26 countries, we showed that DSM-5 GAD is
a common disorder associated with considerable comorbid-
ity and functional impairment. The disorder typically begins
in adulthood, although its onset is later and its course is more
persistent in less developed countries. Although GAD is
found in similar subgroups within the countries examined, it
is more prevalent and impairing in high-income than in low-
or middle-income countries. Probing the mechanisms under-
lying these cross-national differences will advance under-
standing of GAD and inform debates regarding its validity
and global relevance.
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